score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High		Clinical evidence	Clinical evidence	Somatic Variant	TP53	Missense	p.H179R	0.8622	370.0	0.0	0.0								Investigate Actionability - Low	Lenalidomide	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability - High	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	423.0	0.9291	1.0	TP53 p.H179R (Missense)		MO_1339	MO_1339-TM	MO_1339-NB
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MO_1339		
Biologically Relevant				Somatic Variant	PMS2	Frameshift	p.RQ287fs	0.3353	167.0	0.0	0.0																			0	0.0	0.0	0.0	PMS2 p.RQ287fs (Frameshift)		MO_1339	MO_1339-TM	MO_1339-NB
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R473W	0.1558	552.0	0.0	0.0																			0	12.0	0.0	0.1077	RUNX1T1 p.R473W (Missense)		MO_1339	MO_1339-TM	MO_1339-NB
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.D238Y	0.6219	521.0	0.0	0.0																			0	423.0	0.6998	1.0	ESRP1 p.D238Y (Missense)		MO_1339	MO_1339-TM	MO_1339-NB
Biologically Relevant				Copy Number	ETV6	Deletion				0.0	0.0																			0				ETV6 Deletion		MO_1339	MO_1339-TM	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 p.RQ287fs (Frameshift), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PMS2 p.RQ287fs (Frameshift), MSH3 p.PPA66del (Deletion)		MO_1339		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.508																							0				COSMIC Signature 1 (51%)		MO_1339		
Biologically Relevant				Mutational Signature	COSMIC Signature 6		0.291																							0				COSMIC Signature 6 (29%)		MO_1339		
